BeiGene has opened its new $800 million Hopewell, NJ-based biologics manufacturing facility, which additionally homes the corporate’s medical R&D capabilities.
Editor’s word: this story was initially printed on BioPharmInternational.com.
Oncology firm BeiGene has opened its new biologics manufacturing facility on the Princeton West Innovation Campus in Hopewell, NJ. The $800 million facility represents the corporate’s flagship facility in the USA and likewise homes a medical R&D heart. The funding is a part of the corporate’s strategic objective to develop its built-in manufacturing and R&D footprint within the US, in line with a July 23, 2024 firm press launch.
BeiGene has greater than 30 molecules at clinical- or commercial-stage growth. The brand new 42-acre facility provides the corporate flexibility to scale manufacturing of those drug candidates presently and sooner or later to fulfill most cancers affected person wants. The Hopewell web site contains roughly 400,000 ft2 of area devoted to commercial-stage biologic manufacturing capability and consists of extra area to develop over time as BeiGene’s pipeline matures.
The ability strengthens BeiGene’s late-stage analysis and medical growth capabilities. The corporate’s oncology pipeline addresses 80% of worldwide cancers utilizing modalities similar to focused degraders and antibody drug conjugates in addition to monoclonal antibodies and conventional small molecules. The brand new facility allows the corporate to provide at scale, which reduces prices and ensures provide chain resiliency. The corporate goals to keep away from international disruptions, defend capability, and quickly adapt to the most recent revolutionary modalities, in line with an organization press launch.
“BeiGene has skilled unprecedented international development, and the addition of our facility on the Princeton West Innovation Campus provides manufacturing and medical growth capabilities that may additional strengthen our differentiated technique, which leverages velocity, effectivity, and know-how to advance high quality medicines quicker for sufferers,” mentioned John V. Oyler, co-founder, chairman, and CEO of BeiGene, within the press launch. “We’re proud to be part of New Jersey’s biopharmaceutical neighborhood that’s wealthy in analysis and growth and manufacturing expertise. We stay up for deepening {our relationships} with key regional analysis establishments as we advance our sturdy pipeline of next-generation hematology and strong tumor medicines and proceed to emerge as a number one international oncology innovator.”
The corporate expects to create tons of of expert high-tech jobs on the web site by the top of 2025. BeiGene initially introduced its intent to build on the Hopewell web site in November 2021 (1).
“I’m thrilled by BeiGene’s contribution to our state’s thriving biopharmaceutical sector,” mentioned Governor Phil Murphy, within the launch. “The opening of BeiGene’s flagship campus underscores our dedication to fostering innovation and creating high-tech jobs within the Backyard State. We stay up for the constructive affect BeiGene could have on our economic system and the developments they are going to carry to most cancers remedy. This vital funding highlights New Jersey’s function as a world chief in pharmaceutical manufacturing, analysis, and growth. We’re proud to help BeiGene’s mission to develop inexpensive and accessible therapies for most cancers sufferers worldwide.”
As a part of BeiGene’s sustainability efforts, the corporate has invested in sustainability measures each within the buildings and surrounding the 42 acres of the positioning. These measures embrace a heating and cooling system that employs recycled wastewater from the onsite wastewater remedy plant for the cooling towers and solar-ready functionality.
Reference
1. BeiGene. BeiGene Closes on Property for New U.S. Manufacturing and Medical R&D Middle. Press Launch, Nov. 23, 2021.
Supply: BeiGene